Compare · BRKR vs FLDM
BRKR vs FLDM
Side-by-side comparison of Bruker Corporation (BRKR) and Fluidigm Corporation (FLDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- BRKR operates in Industrials, while FLDM operates in Capital Goods - the two are in different parts of the market.
- BRKR is the larger of the two at $9.81B, about 40.1x FLDM ($244.6M).
- BRKR has hit the wire 11 times in the past 4 weeks while FLDM has been quiet.
- BRKR has more recent analyst coverage (21 ratings vs 0 for FLDM).
- Company
- Bruker Corporation
- Fluidigm Corporation
- Price
- $36.55+0.74%
- $3.70-7.27%
- Market cap
- $9.81B
- $244.6M
- 1M return
- +2.11%
- -
- 1Y return
- -7.88%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2011
- News (4w)
- 11
- 0
- Recent ratings
- 21
- 0
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has a collaboration agreement with the Karolinska Institutet for research applications and product development utilizing CyTOF XT. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Latest BRKR
- Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
- Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
- Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
- Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
- SEC Form 4 filed by Munch Mark
- Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026
- SEC Form DEFA14A filed by Bruker Corporation
- SEC Form DEF 14A filed by Bruker Corporation
- SEC Form 3 filed by new insider Bernard Thierry
- Bruker Corporation filed SEC Form 8-K: Leadership Update
Latest FLDM
- No More Free COVID-19 At-Home Tests, Federal Government Says
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- SEC Form 4: Colston Bill was granted 30,914 shares, increasing direct ownership by 109% to 59,288 units
- SEC Form 4: Burbach Gerhard F was granted 30,914 shares, increasing direct ownership by 47% to 96,827 units
- SEC Form 4: Madaus Martin D was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Witney Frank was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Paya Carlos V was granted 30,914 shares, increasing direct ownership by 44% to 100,468 units
- SEC Form 4: Casdin Eli was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Clague Laura was granted 30,914 shares, increasing direct ownership by 65% to 78,415 units